Brief: BridgeBio Pharma Q2 Net Income USD -183.758 Million

BridgeBio Pharma

05/08/2025 21:01

Overview

BridgeBio Q2net total revenue of $110.6 mln beats analyst expectations, per LSEG data

The biopharmaceutical company ended Q2 with $756.9 mln in cash

Attruby net product revenue reached $71.5 mln in the U.S. for Q2

Outlook

BridgeBio expects topline results from FORTIFY in fall 2025

Company anticipates CALIBRATE results in fall 2025

BridgeBio sees PROPEL 3 results in early 2026

Result Drivers

ATTRUBY LAUNCH - Accelerating launch with 3,751 unique prescriptions by 1,074 prescribers, driven by growth in treatment-naïve segment

CLINICAL EFFICACY - New analyses from ATTRibute-CM study show significant reduction in cardiovascular events and mortality for ATTR-CM patients

PIPELINE ADVANCEMENT - Progress in Phase 3 trials for BBP-418 and encaleret

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$110.57 mln
$91.40 mln (17 Analysts)
Q2 Net Income
-$183.76 mln
Q2 Basic EPS
-$0.95
Q2 Operating Income
-$134.28 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 20 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for BridgeBio Pharma Inc is $60.00, about 20.4% above its August 4 closing price of $47.75

Press Release: ID:nGNX87fdFW

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)